Intravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusion

Autor: Emel Okulu, Omer Erdeve, Ilknur Kilic, Ozgur Olukman, Sebnem Calkavur, Gokhan Buyukkale, Merih Cetinkaya, Dilek Ulubas, Nihal Demirel, Deniz Hanta, Sabahattin Ertugrul, Nazli Dilay Gultekin, Oguz Tuncer, Nihat Demir, Leyla Bilgin, Nejat Narli, Duran Yildiz, Demet Terek, Ozge Altun Koroglu, Canan Seren, Elif Ozyazici, Ramazan Ozdemir, Hatice Turgut, Fatma Narter, Yasemin Akin, Ahmet Ozyazici, Aysegul Zenciroglu, Huseyin Selim Asker, Zeynel Gokmen, Musa Salihli, Ali Bulbul, Umut Zubarioglu, Begum Atasay, Esin Koc, Turkish Neonatal Society IVIG Study Group, Kurthan Mert, Akan Yaman, Evrim Alyamac Dizdar, Nurdan Uras, Berna Hekimoglu, Ayse Engin Arisoy, Yasemin Senel, Eren Ozek, Hulya Ozdemir, Kadir Tekgunduz, Ibrahim Caner, Sema Tanriverdi, Dilek Sarici, F. Mehmet Kislali, Didem Aliefendioglu, Nilufer Guzoglu, Cumhur Aydemir, Muhittin Celik, Belma Saygili Karagol, Bilge Bayraktar, Suzan Sahin, Ibrahim Murat Hirfanoglu, Betul Acunas, Ferda Ozlu, Ayse Ecevit, Cengiz Arcagok, Neslihan Tekin, Hacer Ergin, Selda Arslan, Asuman Coban

Publikováno v: Frontiers in Pediatrics, Vol 10 (2022)

IntroductionIntravenous immunoglobulin (IVIG) has been widely used to treat the hemolytic disease of the newborn (HDN). Although it has been shown that IVIG treatment reduces the duration of phototherapy and hospitalization, the use of IVIG in hemoly

Externí odkaz: https://doaj.org/article/3078603091f1445a90ba776145affc74